» Articles » PMID: 16670298

Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-1

Overview
Journal J Immunol
Date 2006 May 4
PMID 16670298
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Immunodominance has been well-demonstrated in many antiviral and antibacterial systems, but much less so in the setting of immune responses against cancer. Tumor Ag-specific CD8+ T cells keep cancer cells in check via immunosurveillance and shape tumor development through immunoediting. Because most tumor Ags are self Ags, the breadth and depth of antitumor immune responses have not been well-appreciated. To design and develop antitumor vaccines, it is important to understand the immunodominance hierarchy and its underlying mechanisms, and to identify the most immunodominant tumor Ag-specific T cells. We have comprehensively analyzed spontaneous cellular immune responses of one individual and show that multiple tumor Ags are targeted by the patient's immune system, especially the "cancer-testis" tumor Ag NY-ESO-1. The pattern of anti-NY-ESO-1 T cell responses in this patient closely resembles the classical broad yet hierarchical antiviral immunity and was confirmed in a second subject.

Citing Articles

Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses.

Duarte J, Woods K, Quigley L, Deceneux C, Tutuka C, Witkowski T Cancers (Basel). 2021; 13(8).

PMID: 33918976 PMC: 8069442. DOI: 10.3390/cancers13081805.


PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses.

Dolen Y, Gileadi U, Chen J, Valente M, Creemers J, van Dinther E Front Immunol. 2021; 12:641703.

PMID: 33717196 PMC: 7947615. DOI: 10.3389/fimmu.2021.641703.


Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.

Cebon J, Gore M, Thompson J, Davis I, McArthur G, Walpole E J Immunother Cancer. 2020; 8(1).

PMID: 32317292 PMC: 7204806. DOI: 10.1136/jitc-2019-000410.


Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori.

Yang Y, Chen L, Sun H, Guo H, Song Z, You Y J Nanobiotechnology. 2019; 17(1):6.

PMID: 30660182 PMC: 6339695. DOI: 10.1186/s12951-019-0441-y.


Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

Bethune M, Li X, Yu J, McLaughlin J, Cheng D, Mathis C Proc Natl Acad Sci U S A. 2018; 115(45):E10702-E10711.

PMID: 30348802 PMC: 6233129. DOI: 10.1073/pnas.1810653115.